AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies focused on immunology and inflammatory diseases, particularly chronic fibrotic conditions. The company's lead program, Ontunisertib (AGMB-129), is an oral small molecule inhibitor of ALK5/TGFβR1 currently in Phase 2a trials for fibrostenosing Crohn's disease. The company is also advancing AGMB-447, an inhaled ALK5/TGFβR1 inhibitor in Phase 1 development for idiopathic pulmonary fibrosis, and AGMB-101, a HGF-mimetic monoclonal antibody designed to stimulate MET receptor signaling for antifibrotic and regenerative activity, which remains in preclinical development.
As a clinical-stage company, AgomAb Therapeutics does not currently generate revenue from product sales. The organization is supported by 57 full-time employees and operates from its headquarters in Antwerp, Belgium, where it was incorporated in 2017. The company is publicly listed on Nasdaq and maintains a market capitalization of approximately $0.8 billion. Revenue generation is expected only upon potential regulatory approval and commercialization of its pipeline candidates, which remain in early-to-mid stage clinical development.
No 10-K filings found.